256.38MMarket Cap-1930P/E (TTM)
2.785High2.592Low368.91KVolume2.740Open2.710Pre Close982.36KTurnover0.57%Turnover RatioLossP/E (Static)96.93MShares4.27052wk High2.47P/B170.00MFloat Cap1.54052wk Low--Dividend TTM64.27MShs Float17.620Historical High--Div YieldTTM7.12%Amplitude1.540Historical Low2.662Avg Price1Lot Size
Poseida Therapeutics Stock Forum
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
No comment yet